Dermavant Presents New Data on Treatment of Patients with Skin of Color from ADORING 1 and 2 Phase 3 Pivotal Trials of VTAMA® (tapinarof) Cream, 1% in Adults and Children 2 Years of Age an...
Roivant Sciences Ltd. (ROIV)
Company Research
Source: Yaho
– In ADORING 1 and ADORING 2, 57.1% and 58.1% of patients, respectively, with Fitzpatrick skin type (IV, V, VI) achieved an EASI75 response at Week 8 – LONG BEACH, Calif. & BASEL, Switzerland, March 08, 2024 BUSINESS WIRE )--Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced new data on treatment of patients with skin of color from its Phase 3, ADORING 1 and ADORING 2 pivotal trials of VTAMA®(tapinarof) cream, 1% in adults and children 2 years of age and older with atopic dermatitis (AD) at the 2024 American Academy of Dermatology (AAD) Annual Meeting, being held from March 8-12 in San Diego, CA. VTAMA cream is a novel, aryl hydrocarbon receptor agonist in development as a once-daily, cosmetically elegant, and steroid-free, topical cream for both acute treatment and long-term management of AD. VTAMA cream, 1% is currently approved for the topical treatment of plaque psoriasis i
Show less
Read more
Impact Snapshot
Event Time:
ROIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ROIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ROIV alerts
High impacting Roivant Sciences Ltd. news events
Weekly update
A roundup of the hottest topics
ROIV
News
- Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary SarcoidosisBusiness Wire
- Roivant Sciences: Cashing In On Vants And Ventures [Seeking Alpha]Seeking Alpha
- OSR Holdings and SillaJen have entered into a Memorandum of Understanding to collaboratively pursue the development of innovative therapeutics and enter the U.S. market [Yahoo! Finance]Yahoo! Finance
- Roivant Sciences Ltd. (NASDAQ: ROIV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.MarketBeat
- Arbutus Biopharma jumps after patent victory in fight with Moderna [Seeking Alpha]Seeking Alpha
ROIV
Earnings
- 2/13/24 - Beat
ROIV
Sec Filings
- 4/26/24 - Form 4
- 4/26/24 - Form 4
- 4/26/24 - Form 4
- ROIV's page on the SEC website